Clinical, Cognitive, and Neurobiological Correlates of Impaired Timing Abilities Associate to Cannabis Use: a Systematic Review

Time perception received growing interest in psychiatry for its psychopathological implications. Cannabis use can cause a subjective experience of temporal perception alteration and increases the risk of emergence of mental illnesses such as psychotic and mood disorders. In this framework, we systematically reviewed the findings regarding the clinical, cognitive, and neurobiological correlates of time alterations due to cannabis consumption. According to preclinical results, cannabis exerts a dose-dependent time overestimation, associated with motor inhibition and circadian alterations. Clinical results reported that cannabis impair time estimation and time reproduction abilities, causing subjective temporal fragmentation and depersonalization symptoms. The alteration of timing mediated by cannabis use might depend on a dopaminergic indirect action and on structural, functional, and metabolic alterations of the cerebello-thalamo-cortical circuit. Despite the potential interest, however, only few studies explored the link between cannabis-induced alterations of time processing and psychiatric symptoms.

A single-center real-life study on the use of medical cannabis in patients with dystonia

While cannabis-based medicine is being commonly used in patients with movement disorders, there is a scarcity of publications regarding the effect of cannabis on dystonia. We aimed to describe medical cannabis use in patients with dystonia and related pain. We employed a structured interview to obtain data on the cannabis treatment regimen, perception of effectiveness and side effect profile. Eligible participants were patients diagnosed with dystonia from the movement disorders unit at the Tel-Aviv Medical Center who had used licensed medical cannabis between January 2019 and January 2021.

A Retrospective Medical Record Review of Adults with Non-Cancer Diagnoses Prescribed Medicinal Cannabis

Research describing patients using medicinal cannabis and its effectiveness is lacking. We aimed to describe adults with non-cancer diagnoses who are prescribed medicinal cannabis via a retrospective medical record review and assess its effectiveness and safety. From 157 Australian records, most were female (63.7%; mean age 63.0 years). Most patients had neurological (58.0%) or musculoskeletal (24.8%) conditions. Medicinal cannabis was perceived beneficial by 53.5% of patients.

Cannabidiol for neurodegenerative disorders: A comprehensive review

This review briefly discusses the role of inflammation and oxidative stress in neurodegeneration and demonstrates the neuroprotective effect of cannabidiol, highlighting its general mechanism of action and disease-specific pathways in Parkinson’s disease (PD) and Alzheimer’s disease (AD). Furthermore, we have summarized the preclinical and clinical findings on the therapeutic promise of CBD in PD and AD, shed light on the importance of determining its therapeutic window, and provide insights into identifying promising new research directions.

Cannabidiol A Race To Relief

Authors: Nishi Whiteley and Ethan Russo, MD Published in HerbalGram 2020 Introduction Few chemical compounds have enjoyed such a rapid ascent to market acceptance and consumer popularity as CBD. According…

Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease

Authors: Serena Silvestro, Giovanni Schepici, Placido Bramanti, and Emanuela Mazzon Published in Molecules November 2020 Abstract The Cannabis sativa plant contains more than 120 cannabinoids. With the exceptions of ∆9-Cannabidiol…